New indication for Byetta

Byetta (exenatide) is now licensed for use alongside insulin.

The dose of insulin may need to be reduced when Byetta is used as an adjunct, especially in patients at risk of hypoglycaemia
The dose of insulin may need to be reduced when Byetta is used as an adjunct, especially in patients at risk of hypoglycaemia

Byetta (exenatide) is indicated as an adjunct to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes who have not achieved adequate glycaemic control with these agents.

In a 30-week study, patients received twice-daily exenatide or placebo, in addition to insulin glargine (with or without metformin, pioglitazone or both). The dose of insulin glargine was titrated to achieve a target fasting plasma glucose of approximately 5.6mmol/l.

At the end of the study, patients receiving exenatide (n=137) showed greater reductions in HbA1c and body weight than those on placebo (n=122). HbA1c declined by 1.7% in the exenatide group and 1.0% in the placebo group. From baseline, body weight decreased in the exenatide group by 1.8kg but increased by 1.0kg in the control group.

A greater proportion of patients achieved HbA1c targets of <7% and ≤6.5% in the exenatide group than in the placebo group: 56% versus 29% and 42% versus 13%, respectively.

View Byetta drug record

Further information: Lilly Eli & Co Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more